New York, June 22, 2026, 07:11 EDT
- Pfizer Inc (NYSE:PFE) was last quoted at $25.21 before the regular NYSE session, after a 70-cent drop in the prior trading session.
- CFO Dave Denton will leave on August 15; Cecile Guegan becomes interim CFO on August 16 while Pfizer searches for a permanent successor.
- The fresh technical read: the stock is trading at about 8.7 times the midpoint of Pfizer’s 2026 adjusted EPS guide, while Thursday’s 70-cent fall implies about $4.0 billion of equity value lost using Pfizer’s own share-count assumption.
Pfizer Inc (NYSE:PFE) entered Monday pinned near last week’s selloff, with investors still weighing the planned departure of finance chief Dave Denton against the company’s promise of post-2028 growth.
For NYSE:PFE, the timing matters. Regular NYSE trading had not opened at the dateline time; the exchange’s core session runs from 9:30 a.m. to 4:00 p.m. ET, and Friday was a Juneteenth market holiday, making Thursday’s reaction the last full trading signal.
Pfizer said Denton will step down on August 15 to take a consumer-goods role. Guegan, now senior vice president of finance for Pfizer’s global biopharmaceutical business, will become interim CFO the next day. Chief Executive Albert Bourla called Denton a “steady and trusted steward” and said he had “every confidence” in Guegan’s ability to lead the finance group. Pfizer
The stock fell 3.1% to $25.10 in early trading after the announcement on Thursday, Reuters reported. Scotiabank analyst Louise Chen said the exit raised concerns about Pfizer’s 2026 forecast, succession planning and the timing of the move as the company prepares to enter the obesity-drug market.
That makes the tape look more like an execution discount than a simple personnel move. Pfizer’s last quoted price of $25.21 compares with a company market value of about $144.5 billion, while the 70-cent fall from the prior close works out to about $4.0 billion of implied value using Pfizer’s 5.74 billion 2026 share-count assumption. Adjusted EPS, or earnings per share excluding certain items, is guided at $2.80 to $3.00 for 2026; at the midpoint, the stock is on roughly 8.7 times that figure.
That is the overlooked setup. The multiple is low, but the market is asking whether the “E” in that price-to-earnings calculation is steady enough. Pfizer expects 2026 revenue of $59.5 billion to $62.5 billion, with COVID-19 product sales down about $1.5 billion from 2025 and another roughly $1.5 billion hit from loss of exclusivity, meaning patent or regulatory protection ending and cheaper rivals entering. Pfizer
Broader markets gave little cover. U.S. stock-index futures were muted early Monday after Friday’s public holiday, while investors watched U.S.-Iran talks and Thursday’s PCE inflation data, the Federal Reserve’s preferred inflation gauge. That makes Pfizer’s move easier to read as company-specific rather than just part of a weak tape.
The competitive comparison is Eli Lilly (NYSE:LLY), not the old vaccine group. Pfizer is trying to build a place in obesity drugs after buying Metsera, while Lilly already has scale; Bourla told Reuters in May that Pfizer was surprised by how large the international weight-loss market had become after Lilly’s report. Aamir Malik, Pfizer’s U.S. commercial chief, said Pfizer had “unique capabilities” and already dealt with almost 60% of doctors likely to write obesity-drug prescriptions. Reuters
Analysts have not dismissed the story. J.P. Morgan’s Chris Schott said in May that investors needed more clinical data and lower pipeline risk before sentiment improved, while RBC Capital’s Trung Huynh called Pfizer a “catalyst story, not an earnings story.” Citi’s Geoff Meacham said 22% growth in newly launched and acquired products showed the commercial portfolio could help offset COVID declines. Reuters
But the risk is plain. If obesity data disappoint, if newly acquired cancer and migraine assets do not scale fast enough, or if the permanent CFO search drags into budget season, Pfizer’s low earnings multiple may stay low. A higher dividend yield can support a stock for a while; it does not, by itself, answer whether post-COVID Pfizer can grow again.
